2+ day, 13+ hour ago   (355+ words) Yahoo Finance Oops, something went wrong U.S. markets close in 2h 6m Perelel and Bluestone Lane Launch National Partnership Bringing Clinically Studied Triple-Support Protein to 65+ Cafés Beginning September 10, Bluestone Lane introduces a year-long national partnership, with three seasonal drops featuring Perelel's clinically-proven Triple-Support…...

3+ day, 13+ hour ago   (65+ words) The Alzheimer's Agitation Non-Antipsychotic Drug Therapy openPR.com The Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market is Projected to Experience Robust Growth with a 14.3% CAGR Forecast Press release from: The Business research company Permanent link to this press release: You can…...

1+ week, 20+ hour ago   (533+ words) The clinical trial is recruiting 1,600 healthy adults aged 55 to 80 internationally An NHS trust says it has become the first in Europe to join a trial examining if a new drug can delay or prevent the onset of Alzheimer's. Surrey and…...

1+ week, 2+ day ago   (417+ words) Canada's Drug Agency reversed its do-not-reimburse draft, and pCPA negotiations decide what plans pay next Canada's Drug Agency will back public reimbursement of the Alzheimer's treatment LEQEMBI (lecanemab) only if its price falls. Canada's Drug Agency (CDA-AMC) limited coverage to…...

1+ week, 2+ day ago   (472+ words) LEQEMBI SC-AI approved in China for early Alzheimer's treatment, offering at-home administration options and reduced healthcare resource needs. LEQEMBI SC-AI is a subcutaneous autoinjector formulation of lecanemab, approved for treating mild cognitive impairment due to Alzheimer's disease. LEQEMBI SC-AI was…...

1+ week, 3+ day ago   (249+ words) Stack3d BUY ONE GET ONE FREE AT NINJA Check out Stack3d's most popular stories before you go Ostrovit throws in DigeZyme to help differentiate its latest protein powder European supplement giant OstroVit already has plenty of traditional protein powders, and we…...

1+ week, 4+ day ago   (133+ words) lifesciencenordic.com Bioarctic's research partner Eisai has received a final recommendation from Canada's drug agency supporting public reimbursement of Leqembi (lecanemab) for eligible patients with early Alzheimer's disease. Bioarctic said in a press release. Eli Lilly to acquire Merida Biosciences…...

1+ week, 4+ day ago   (402+ words) The Clinical Trial Vanguard Canada’s Drug Agency Issues Positive Reimbursement Recommendation for Lecanemab Canada’s Drug Agency reversed course on lecanemab in roughly five months, flipping from a February 2026 recommendation against public reimbursement to a final positive recommendation issued September 1 — and…...

1+ week, 5+ day ago   (125+ words) Barchart.com We've received your inquiry. A specialist will reach out within 1 business day. Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease All information and data in this article is solely…...

1+ week, 5+ day ago   (456+ words) Canada's Drug Agency recommends public reimbursement for LEQEMBI® in eligible Alzheimer’s patients, advancing access in Canada. LEQEMBI® is a monoclonal antibody designed to treat mild cognitive impairment or mild dementia due to Alzheimer’s disease. Canada’s Drug Agency (CDA-AMC) issued the…...